Advancing Non-Viral Gene Editing by Leveraging Hyperactive Integrases to Efficiently Deliver Targeted Large Cargo

  • Leveraging evolved phage integrases for non-viral, site-specific genomic integration to enhance safety and minimize off-target effects
  • Engineering a super-efficient non-viral delivery system for large DNA fragments to overcome current limitations and unlock complex gene therapies
  • Delivering exceptionally large therapeutic gene payloads (up to 16kb) to address complex multi-gene disorders and reduce manufacturing costs